United Therapeutics Leaders Sell $7.8 Million in Stock
United Therapeutics has drawn substantial institutional interest, with Voya increasing its holdings by 46% in the third quarter and several major investors reporting new positions. Investors are weighing the company’s potential xenotransplantation program, including its first UThymoKidney transplant in the EXTEND trial, against questions about valuation: one analysis finds the shares undervalued relative to a growth-adjusted earnings benchmark, while another assessment flags them as potentially overvalued. CEO Martine Rothblatt and Executive Vice President Paul Mahon each sold shares worth about $3.1 million and $4.7 million, respectively, after exercising options; both transactions were made under prearranged 10b5-1 plans. In its latest reported quarter, revenue rose 4.1% year over year to $832.5 million and exceeded analyst expectations, while earnings per share of $5.71 fell short of forecasts.
Where do you stand?
How it spread





